Celltrion, Inc.
In the news
- South Korea's Celltrion exports coronavirus tests to US Aug 13, 2020
- Coronavirus: Week of July 12 to July 18, Australian PM seeks to delay parliament Jul 18, 2020
- Glove makers and net stocks see COVID-19 boom in bear market Jul 1, 2020
- SK Biopharm highlights drugs pipeline ahead of planned $800m IPO Jun 15, 2020
- Takeda sells 18 drugs to South Korea's Celltrion in $278m deal Jun 12, 2020 See more articles on Celltrion, Inc.
Company Background
Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.
Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.
In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.
Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.
Business Summary
Financial Highlights
| Dec 2019 | KRW | USD |
| Revenue | 1,128.45B | 967.65M |
| Gross Profit | 623,222.91M | 534.41M |
| Operating income | 378,062.36M | 324.18M |
| Income before tax | 374,013.70M | 320.71M |
| Net income | 297,556.85M | 255.15M |
| EBITDA | 537,282.22M | 460.71M |
| Diluted EPS | 2,218.68 | 1.90 |
| Dividends Per Share | 0 | 0 |
| Total Assets | 3,893.69B | 3,366.93M |
| Total liabilities | 986,733.41M | 853.24M |
| Total equity | 2,794.15B | 2,416.14M |
| Operating cash flow | 468,031.66M | 401.33M |
| Currency in KRW | Currency in USD |
Historical Data
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | |
| Revenue | 603,412.76M | 670,580.96M | 949,079.96M | 982,074.95M | 1,128.45B |
| Gross Profit | 361,042.87M | 388,407.95M | 685,318.99M | 541,284.44M | 623,222.91M |
| Operating income | 258,922.92M | 249,614.31M | 507,771.41M | 338,291.33M | 378,062.36M |
| Income before tax | 162,901.39M | 228,752.75M | 491,503.19M | 317,725.82M | 374,013.70M |
| Net income | 154,089.61M | 177,994.50M | 382,467.03M | 261,841.76M | 297,556.85M |
| EBITDA | 341,097.00M | 338,289.64M | 605,721.68M | 465,057.52M | 537,282.22M |
| Diluted EPS | 1,187.40 | 1,330.99 | 2,794.58 | 1,943.56 | 2,218.68 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 2,825.98B | 3,117.56B | 3,410.79B | 3,628.33B | 3,893.69B |
| Total liabilities | 1,015.16B | 914,607.61M | 975,863.55M | 992,561.59M | 986,733.41M |
| Total equity | 1,694.23B | 2,053.63B | 2,308.89B | 2,524.02B | 2,794.15B |
| Operating cash flow | 45,199.75M | 230,062.47M | 482,870.20M | 372,074.18M | 468,031.66M |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | |
| Revenue | 533.14M | 577.99M | 839.51M | 892.37M | 967.65M |
| Gross Profit | 318.99M | 334.77M | 606.20M | 491.84M | 534.41M |
| Operating income | 228.77M | 215.14M | 449.15M | 307.39M | 324.18M |
| Income before tax | 143.93M | 197.16M | 434.76M | 288.70M | 320.71M |
| Net income | 136.14M | 153.41M | 338.31M | 237.92M | 255.15M |
| EBITDA | 301.37M | 291.58M | 535.79M | 422.58M | 460.71M |
| Diluted EPS | 1.04 | 1.14 | 2.47 | 1.76 | 1.90 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 2,410.12M | 2,581.19M | 3,186.01M | 3,251.78M | 3,366.93M |
| Total liabilities | 865.77M | 757.25M | 911.55M | 889.55M | 853.24M |
| Total equity | 1,444.91M | 1,700.31M | 2,156.73M | 2,262.07M | 2,416.14M |
| Operating cash flow | 39.93M | 198.29M | 427.12M | 338.09M | 401.33M |
Valuation Measures
| Dec 2019 | |
| PER | 81.17 |
| ROA | 7.91% |
| ROE | 11.19% |
| Operating margin | 33.50% |
| Profit margin | 26.36% |
Key executives
- Chief Executive Officer & Director: Wu-Sung Ki
- Finance Director: Ho-Seop Lee
- Head-Legal & Compliance Support: Sung-Han Lee
- Vice President: Sang-Joon Lee
- Vice President: Jung-Won Yoon
Shareholders
- SEO JUNG-JIN (22.1%)
- National Pension Service of Korea (9.1%)
- Temasek Holdings Pte Ltd. (Investment Management) (7.4%)
- The Vanguard Group, Inc. (2.2%)
- BlackRock Fund Advisors (1.5%)
- Celltrion, Inc. (0.8%)
- Norges Bank Investment Management (0.8%)
- Mirae Asset Global Investments Co., Ltd. (0.7%)
- Celltrion Inc. Employee Stock Ownership ASSN. (0.5%)
- BlackRock Advisors (UK) Ltd. (0.4%)
Contact Details
- Website:http://www.celltrion.com
- Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
- Phone: +82.32.850.5000
Related Companies
- Celltrion Inc. Employee Stock Ownership ASSN.
- Celltrion Pharm Inc.
Competitors
- Novartis AG
- Pfizer Inc.
- Mylan N.V.
- AbbVie, Inc.
- Amgen Inc.
- Gilead Sciences, Inc.
- Biocon Limited
- Merck KGaA
- SAMSUNG BIOLOGICS Co., Ltd.
- EPIRUS Biopharmaceuticals, Inc.
- Reyon Pharmaceutical Co., Ltd.
- Wooridul Pharmaceutical Ltd.
- Sinocelltech Group Limited Class A
- Mabion SA
- ALTEOGEN Inc.
- PharmAbcine Inc.
- Dexter Studios Co., Ltd.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 27 Oct, 2020
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.